XPhyto Announces Business Strategy and Milestones For 2021 Innovation to Impact
The Pharma Data
JANUARY 17, 2021
Following a successful business year 2020, XPhyto is well positioned to execute on important core milestones in all business divisions, which include the commercialization of infectious disease diagnostics, the clinical validation of transdermal and sublingual drug formulations and continued investment and development in psychedelic medicine.
Let's personalize your content